Health TrialsbyHealthPanel

Database and Biobank of Patients With Hypersensitivity Pneumonitis

ConditionHypersensitivity Pneumonitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNils Hoyer

About this trial

Sub-study of the main Pulmonary Fibrosis Biomarker (PFBIO) cohort (NCT02755441), recruiting patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP). Patients are included for the collection of blood samples and regular clinical data.

The database and biobank will be available for studies of HP, and can be directly compared to the main PFBIO cohort, which has recruited patients with Idiopathic pulmonary Fibrosis (IPF) since 2016.

Biomarkers will be assessed as diagnostic and prognostic. Further subtyping of HP, based on blood markers (including precipitins) will also be possible with the PFBIO-HP project.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of HP at an MDT conference according to the current international guidelines

Age of 18 years or older

The patients must be capable of giving informed consent

Disqualifiers

None

Trial population

All adult patients with an MDT-diagnosis of HP are eligible.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

50 Participants
are grouped into 1 trial group
Group A: Patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP)

Trial outcomes

Primary outcomes

1

Diagnosis of HP

MDT-Diagnosis of HP

Time frame
0 days
2

Exposure to inciting antigen (patient reported)

Known exposure, as reported by the patient

Time frame
0 days
3

Exposure to inciting antigen (measurable)

Measurable exposure, as tested by precipitins

Time frame
0 days
4

Progression free survival

Survival without progression

Time frame
3 years

Secondary outcomes

1

Quality of life questionnaires

SGRQ

Time frame
3 years
2

Pulmonary function test

FVC

Time frame
3 years
3

Pulmonary function test

DLCO

Time frame
3 years
4

Imaging

HRCT scans

Time frame
3 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Nils Hoyer

Lead sponsor

University Hospital, Gentofte, Copenhagen

Sponsor institution

Source ClinicalTrials.gov
Apply now